Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYH2072, a Class 1 new chemical aldosterone synthase inhibitor tablet for uncontrolled hypertension and primary aldosteronism. The highly selective drug has shown in pre-clinical studies that it can significantly reduce plasma aldosterone and blood pressure without affecting cortisol levels, and with favorable pharmacokinetics and safety, CSPC believes it could become a best-in-class therapy for conditions with substantial unmet clinical need; the company has also filed multiple patent applications in China and overseas, underscoring its push to strengthen its innovative cardiovascular portfolio and competitive position in this high-value segment.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on the research, development and commercialization of innovative drugs, including Class 1 new chemical entities, for major therapeutic areas in China and international markets.
YTD Price Performance: 88.72%
Average Trading Volume: 124,058,396
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$100.9B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.